Abiraterone 99% Powder CAS NO (154229-19-3) available for sale

1. Introduction to Abiraterone

Abiraterone, also known as abiraterone acetate, is a medication used in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Developed by inhibiting androgen biosynthesis, abiraterone offers a novel therapeutic approach for managing advanced prostate cancer by targeting the androgen receptor signaling pathway.

2. Pharmacodynamics of Abiraterone

Abiraterone selectively inhibits the enzyme CYP17A1, which plays a crucial role in androgen biosynthesis. By inhibiting both the 17α-hydroxylase and 17,20-lyase activities of CYP17A1, abiraterone suppresses the production of androgens such as testosterone and dehydroepiandrosterone (DHEA), thereby depriving prostate cancer cells of essential growth stimuli.

3. Pharmacokinetics of Abiraterone

Following oral administration, abiraterone acetate is rapidly converted to its active metabolite, abiraterone, primarily in the liver. Its absorption is enhanced when taken with a high-fat meal, as it is highly lipophilic. Abiraterone is extensively bound to plasma proteins, primarily albumin. It undergoes hepatic metabolism via CYP3A4, with the formation of inactive metabolites. The elimination half-life of abiraterone is approximately 12 hours.

4. Clinical Applications of Abiraterone

4.1. Metastatic Castration-Resistant Prostate Cancer (mCRPC) Abiraterone is indicated for the treatment of mCRPC, either in combination with prednisone or prednisolone, for patients who have received prior chemotherapy containing docetaxel, or as a first-line therapy in patients who are chemotherapy-naïve. Clinical trials have demonstrated its efficacy in prolonging overall survival, delaying disease progression, and improving quality of life in patients with mCRPC.

4.2. Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) In addition to its established role in mCRPC, abiraterone has shown promising results in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). When combined with androgen deprivation therapy (ADT), abiraterone improves survival outcomes and delays disease progression in patients with newly diagnosed metastatic prostate cancer.

5. Adverse Effects and Precautions

Common adverse effects associated with abiraterone therapy include hypertension, hypokalemia, fluid retention, and liver function abnormalities. Adverse events such as cardiac disorders, including arrhythmias and heart failure, have been reported, particularly in patients with pre-existing cardiovascular risk factors. Close monitoring of blood pressure, electrolytes, and liver function tests is recommended during abiraterone treatment.

6. Conclusion

Abiraterone represents a significant advancement in the management of advanced prostate cancer, offering patients a targeted therapeutic option that disrupts androgen biosynthesis and androgen receptor signaling. Its efficacy in prolonging survival and improving quality of life has established its role as a standard-of-care treatment in both chemotherapy-naïve and post-chemotherapy settings. However, careful patient selection, monitoring, and management of adverse effects are essential to optimize treatment outcomes and minimize potential risks. Ongoing research efforts continue to explore the optimal sequencing, combination strategies, and potential biomarkers to further enhance the therapeutic benefits of abiraterone in prostate cancer management.